you are viewing a single comment's thread.
The NDA for USA is not an economical problem.If you ask me, why not sell of our own in both Europe and the US?The sails force is 15-20 at each site. Concentrating on the big 5 in Europe is 75% of the patient population.An orphan drug will partly compensate the loss in sell potential through Epicepts own channels. One way is just initially hiring an external firm while you build your own channels.Of course it is a matter of losing time, but having some extra, non diluted, money in. Also the initial delay shortens the 10 year of exclusivity and no competition in the EU.The coin has two sides.Waiting for Godot.